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Background and purpose — The initial outcomes following metal-
on-metal hip arthroplasty (MoMHA) revision surgery performed 
for adverse reactions to metal debris (ARMD) were poor. Fur-
thermore, robust thresholds for performing ARMD revision are 
lacking. This article is the second of 2. The fi rst article considered 
the various investigative modalities used during MoMHA patient 
surveillance (Matharu et al. 2018a). The present article aims to 
provide a clinical update regarding ARMD revision surgery in 
MoMHA patients (hip resurfacing and large-diameter MoM total 
hip arthroplasty), with specifi c focus on the threshold for per-
forming ARMD revision, the surgical strategy, and the outcomes 
following revision. 
Results and interpretation — The outcomes following ARMD 
revision surgery appear to have improved with time for several 
reasons, among them the introduction of regular patient surveil-
lance and lowering of the threshold for performing revision. Fur-
thermore, registry data suggest that outcomes following ARMD 
revision are infl uenced by modifi able factors (type of revision 
procedure and bearing surface implanted), meaning surgeons 
could potentially reduce failure rates. However, additional large 
multi-center studies are needed to develop robust thresholds for 
performing ARMD revision surgery, which will guide surgeons’ 
treatment of MoMHA patients. The long-term systemic effects of 
metal ion exposure in patients with these implants must also be 
investigated, which will help establish whether there are any sys-
temic reasons to recommend revision of MoMHAs
■
Many metal-on-metal hip arthroplasties (MoMHAs) have been 
implanted worldwide in the form of hip resurfacing arthro-
plasty (HRA) and total hip arthroplasty (THA) (Bozic et al. 
2009, NJR 2016). Despite the high failure rates of MoMHAs 
(Smith et al. 2012a, 2012c), it is estimated that at least 80% 
of these implants remain in situ worldwide (AOANJRR 2016, 
NJR 2016). Adverse reactions to metal debris (ARMD) repre-
sent an almost unique mode of arthroplasty failure associated 
with MoMHAs. ARMD is very different from conventional 
modes of arthroplasty failure, such as dislocation, loosening, 
and infection, given the associated soft-tissue problems, the 
potentially progressive and destructive disease nature, as well 
as its development in patients with asymptomatic and seem-
ingly well-functioning MoMHAs (Grammatopoulos et al. 
2009, Liddle et al. 2013, Matharu et al. 2016c). 
Given the prevalence of ARMD revision surgery is increas-
ing (Liddle et al. 2013, AOANJRR 2016, Matharu et al. 
2016b, NJR 2016) it is expected that many more MoMHA 
patients will undergo future revision. However a systematic 
review suggested that there was little good quality evidence 
available regarding the outcomes following MoMHA revision 
surgery performed for ARMD (Matharu et al. 2014a), which 
represents the commonest cause of revision (Matharu et al. 
2016b). This therefore makes it diffi cult for surgeons to coun-
sel patients about the risks of undergoing further procedures.
Furthermore, robust thresholds for performing revision for 
ARMD in MoMHA patients have not been established due to 
a lack of evidence (Matharu et al. 2015). This is refl ected in 
the variable recommendations proposed by worldwide regu-
latory authorities for considering MoMHA revision surgery 
(Canada 2012, MHRA 2012, Therapeutic Goods Administra-
tion 2012, FDA 2013, Hannemann et al. 2013). Knowledge 
of any prognostic factors of outcome following ARMD revi-
sion would assist surgeons when making decisions about the 
threshold (when to recommend revision) and type of revision 
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surgery (which components require revision, and which bear-
ing surface/fi xation methods to use) required in MoMHA 
patients with ARMD.
This article is the second of 2, which aims to provide a clini-
cal update on the investigation and management of MoMHA 
patients. The fi rst article considered the various investigative 
modalities used during MoMHA surveillance, with specifi c 
focus on blood metal ion sampling and imaging (Matharu et 
al. 2018a). The present article considers the threshold for per-
forming revision, the surgical strategy, and the outcomes fol-
lowing ARMD revision surgery when performed in patients 
with MoM HRAs and MoM THAs with femoral head sizes of 
36 mm or greater.
Threshold for ARMD revision surgery
The poor outcomes initially reported following ARMD revi-
sion surgery (Grammatopoulos et al. 2009, de Steiger et al. 
2010) led regulatory authorities and surgeons to widely rec-
ommend performing early revision in MoMHAs with ARMD 
(Grammatopoulos et al. 2009, De Smet et al. 2011, Haddad 
et al. 2011, MHRA 2012, FDA 2013). However, there are 
currently no robust thresholds for performing ARMD revi-
sion surgery, because of lack of evidence. Therefore surgeons 
have diffi culty when managing patients with ARMD: which 
patients to revise and which to keep under surveillance?
The limited evidence base and problems clinicians expe-
rience is highlighted by expert opinion (level 5 evidence) 
(Oxford 2011) commonly being used to manage these patients 
(Hannemann et al. 2013, Berber et al. 2015). In 2012, one UK 
center introduced an internet-based multidisciplinary team to 
assist other centers in managing their MoMHA patients with 
cases referred electronically (Berber et al. 2015). The mul-
tidisciplinary team consists of experts (specialist surgeons 
and radiologists), who meet weekly to recommend manage-
ment decisions based on their experience, regulatory guidance 
(MHRA 2012, FDA 2013), and the latest evidence. The pro-
posed management recommendations have been implemented 
by referring institutions in 92% of cases (Berber et al. 2015).
For some cases management is clear. Timely revision sur-
gery is needed for symptomatic patients with pseudotumors 
that are solid, large, invasive, and destructive to the soft tissues 
and bone, sometimes with neurovascular damage (Pandit et al. 
2008, Grammatopoulos et al. 2009, Langton et al. 2010, Lang-
ton et al. 2013, Liddle et al. 2013). Similarly, asymptomatic 
patients with normal investigations (no imaging abnormalities 
and blood metal ion levels below 2 µg/L) are also straightfor-
ward and do not require revision. This leaves a lot of patients 
where management remains uncertain. Such patients include 
those with moderate to no symptoms with abnormal investi-
gations, which can include non-destructive cystic pseudotu-
mors and/or moderately raised blood metal ion concentrations 
(Almousa et al. 2013, Hasegawa et al. 2014, Goldstein et al. 
2016, Kwon et al. 2016, Matharu et al. 2016c). This uncer-
tainty is highlighted by a recent study where 10 MoMHA 
clinical scenarios were used to assess the management deci-
sions made by international experts from 6 centers (Berber et 
al. 2016). Agreement was inconsistent between centers spe-
cifi cally when managing patients with raised or rising blood 
metal ion concentrations, cystic pseudotumors, and peri-ace-
tabular osteolysis (Berber et al. 2016).
The issue of systemic disease in MoMHA patients contin-
ues to generate interest. The long-term effects of high concen-
trations of cobalt and chromium in the body remain unknown. 
Patients with ARMD may develop systemic symptoms due 
to exposure to high cobalt and chromium concentrations. A 
review reported that MoMHA patients with systemic features 
had median serum cobalt concentrations of 35 (14–288) µg/L, 
with symptoms often resolving after revision to a non-MoM 
articulation (Zywiel et al. 2016). Systemic features appear 
to be extremely rare but can be divided into neurological 
(hearing and visual impairment/loss, peripheral neuropathy, 
and cognitive impairment), cardiovascular (cardiomyopathy, 
breathlessness), and endocrine (hypothyroidism, fatigue, mal-
aise, depression) (Tower 2010, Bradberry et al. 2014, Cheung 
et al. 2016, Zywiel et al. 2016). 
Deaths due to cardiac failure secondary to cobalt toxic-
ity have been reported in MoMHA patients, even following 
revision (Gilbert et al. 2013, Martin et al. 2015). Analysis of 
Australian Veterans data reported an association between ASR 
XL MoM THAs and hospital admission for heart failure in 
elderly male patients (Gillam et al. 2017). However, a larger 
study using National Joint Registry (NJR) data from England 
and Wales demonstrated that MoMHA patients were not at 
increased risk of heart failure compared with non-MoMHA 
patients (Sabah et al. 2018), with the same authors reporting 
that MoMHA patients with high blood metal ion concentra-
tions undergoing comprehensive cardiac investigations had no 
detectable heart pathology (Berber et al. 2017). Although an 
established relationship exists between high metal ion expo-
sure and the development of certain cancers in the occupa-
tional setting (Keegan et al. 2007), population data from the 
NJR and Finnish Arthroplasty Register have yet to demon-
strate any increased risk of cancer or mortality in MoMHA 
patients compared with conventional THA patients at short-
term follow-up (Makela et al. 2012, McMinn et al. 2012, Smith 
et al. 2012b, Kendal et al. 2013, Makela et al. 2014). Currently 
regulatory authorities do not make recommendations for con-
sidering revision surgery in MoMHA patients presenting with 
systemic symptoms (Matharu et al. 2015).
Intraoperative fi ndings and surgical strategy
The surgical management of ARMD has evolved over time, 
with the heterogeneity of ARMD not being appreciated ini-
tially (Grammatopoulos et al. 2009, De Smet et al. 2011, 
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Liddle et al. 2013). Therefore MoMHA revisions performed 
for ARMD can range from simple to more complex cases 
(Liddle et al. 2013).
Simple cases to manage surgically include synovitis with 
minimal tissue damage and metallosis, with a satisfactory 
reconstruction usually achieved with primary conventional 
THA implants. Furthermore, when revising MoM THAs some 
surgeons have advised retaining acetabular and/or femoral 
components when these are well fi xed and well positioned, 
with taper adapters recommended if femoral tapers are not 
severely damaged (Munro et al. 2014, Lainiala et al. 2015, 
Plummer et al. 2016). In such instances procedures may be 
performed where either 1 MoMHA component is revised 
(acetabular or femoral), or both components are retained with 
exchange of the modular components only (femoral head and 
acetabular liner, with or without the use of a taper adapter). 
Complex cases include large pseudotumors that are destruc-
tive to the peri-prosthetic bone and soft tissues, which pass 
through tissue planes and also involve vital neurovascular 
structures (such as the femoral vessels or the sciatic nerve). 
Such complex cases are likely to require extensive reconstruc-
tion with revision THA implants with or without augments. 
Occasionally staged revision procedures for ARMD may be 
considered for severe cases or when infection is also a con-
cern. In addition, surgical expertise from other specialties 
(plastics, vascular, orthopedic oncology, or pelvic surgeons) 
may also be required depending on the lesion anatomy, nature 
of the destruction, and the neurovascular involvement. This 
highlights the importance of performing detailed preoperative 
investigations, and planning for surgeons with other expertise 
to be available at revision as well as the necessary reconstruc-
tive implants (Liddle et al. 2013).
Dealing with large soft-tissue lesions around MoMHAs 
represents a new challenge for arthroplasty surgeons. Given 
the potential risk of ARMD recurrence (Grammatopoulos et 
al. 2009, Matharu et al. 2014a), the aim of revision surgery 
is to excise all metal debris within the soft tissues, including 
pseudotumors, similar to an oncological resection. However, 
in reality this aim can become compromised depending on 
the lesion anatomy, namely if it involves vital neurovascular 
structures and/or the primary soft tissues contributing to hip 
stability.
There is little guidance available regarding the specifi c type 
of reconstruction to manage ARMD revisions in MoMHAs, 
namely which components to revise, and which compo-
nent fi xation methods and bearing surfaces to implant. On 
the basis of the limited current available evidence we have 
made some recommendations about these particular aspects 
given the authors have signifi cant experience with revision of 
MoMHAs for ARMD (Matharu et al. 2014b, Lainiala et al. 
2015, Matharu et al. 2016b).
Selective component revisions are simpler surgically com-
pared with revising the entire construct, especially in MoM 
THAs. Theoretically single component and modular compo-
nent only revisions reduce the risks associated with remov-
ing the acetabular and/or femoral components. However even 
well-fi xed components, especially the acetabulum, should 
be removed if they are clearly malpositioned (De Smet et al. 
2011). On the femoral side special attention should be paid to 
assess the trunnion in MoM THAs; if it is severely worn the use 
of a taper adapter is not appropriate. Instead the stem should 
be removed, with extended trochanteric osteotomies some-
times required to facilitate the removal of a well-fi xed femoral 
component. Therefore the use of single component or modular 
component only revisions should not be overused, with recent 
NJR data reporting that employing the latter strategy when 
revising MoM THAs with ARMD was associated with twice 
the risk of re-revision compared with all component revisions 
and compared with hips undergoing acetabular component 
only revisions (Matharu et al. 2017a). Instability and infection 
were the commonest reasons for re-revision following these 
modular component only exchanges (Matharu et al. 2017a).
No studies have yet shown the superiority of one type of 
fi xation method over another following ARMD revision. 
Uncemented implants have been favored at ARMD revision, 
presumably because patients who received MoMHAs were 
young and active (De Smet et al. 2011, Matharu et al. 2017a). If 
concerns exist about osseointegration of the revision prosthe-
sis on the femoral side, which may be due to associated bone 
loss or elderly patients with osteoporotic bone, we suggest 
using cemented primary implants or revision implants (often 
uncemented), with proximal femoral replacements sometimes 
needed in severe cases. Uncemented revision implants with or 
without augments, pelvic plating, and/or cages are often used 
for managing bone loss on the acetabular side (Liddle et al. 
2013, Munro et al. 2014, Lainiala et al. 2015). Recent NJR 
data in MoMHAs revised for ARMD suggested acetabular 
bone grafting was associated with twice the risk of re-revision 
compared with not grafting, with the authors suggesting that 
the higher failures associated with bone grafting may be either 
due to the need for more complex reconstructions thus neces-
sitating the graft, or because of problems with the graft itself 
(such as infection) (Matharu et al. 2017a).
It is universally accepted that ARMD revisions should receive 
a non-MoM bearing surface, given the potential for high wear 
from MoM bearings (Kwon et al. 2010, Langton et al. 2010) 
and the poor outcomes subsequently reported when MoM 
bearings were used at revision (Liddle et al. 2013, Matharu 
et al. 2014b, Pritchett 2014). Recent NJR data observed that, 
in ARMD revisions, implanting ceramic-on-ceramic bearing 
surfaces was associated with an 86% increased risk of re-revi-
sion compared with ceramic-on-polyethylene bearings; the 
outcomes for metal-on-polyethylene were not signifi cantly 
different when compared with either of these ceramic bearing 
couples (Matharu et al. 2017a). However, this study was not 
able to perform further analyses on the type of polyethylene 
(standard vs. highly cross-linked) as this particular informa-
tion was not available for the authors to assess. 
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In cases with well-functioning abductors and good soft-tis-
sue balance, we currently recommend using ceramic femoral 
heads combined with highly cross-linked polyethylene liners. 
This strategy also minimizes the risk of further metal wear 
debris and/or corrosion that can be generated when using 
metal-on-polyethylene revision bearings, which can be a 
source of ARMD recurrence (Munro et al. 2014, Whitehouse 
et al. 2015, Plummer et al. 2016). When stability is compro-
mised because of soft-tissue problems, options include large-
head ceramic-on-ceramic bearing surfaces, large ceramic 
heads with thin cross-linked polyethylene liners, dual mobil-
ity cups, or constrained acetabular liners (De Smet et al. 2011, 
Liddle et al. 2013, Pritchett 2014, Lainiala et al. 2015). In 
these complex cases with poor soft tissues there is no com-
pelling evidence to recommend any of these options over the 
others (Jones 2016). However, retaining the original 1-piece 
MoM acetabular component (with a worn internal surface) 
and combining it with a Dual Mobility head could potentially 
increase the risk of polyethylene wear.
Outcomes following ARMD revision surgery
Evidence available and patient demographics
A systematic review undertaken in 2013 identifi ed 6 stud-
ies reporting the outcomes (complications, re-revision sur-
gery, and post-revision functional outcomes) following 216 
MoMHA revisions performed for ARMD (Matharu et al. 
2014a). This review was updated to include eligible studies 
up to the end of 2016 using the methods described (see Sup-
plementary data). Including the 6 initial studies a total of 15 
unique studies were eligible for inclusion with 803 MoMHA 
revisions for ARMD (Grammatopoulos et al. 2009, De Smet 
et al. 2011, Ebreo et al. 2011, Rajpura et al. 2011, Liddle et 
al. 2013, Su and Su 2013, Matharu et al. 2014b, Munro et al. 
2014, Norris et al. 2014, Pritchett 2014, Cip et al. 2015, Lai-
niala et al. 2015, Stryker et al. 2015, van Lingen et al. 2015, 
Liow et al. 2016). 1 further study reported the outcomes fol-
lowing 16 ARMD revisions at extended follow-up (median of 
10 years) (Matharu et al. 2017b). All included studies were 
either case-control or cohort studies graded as level 4 evidence 
(Oxford 2011), with the majority being retrospective. We 
acknowledge that a number of registry reports of outcomes 
following MoMHA revision surgery exist (de Steiger et al. 
2010, Wong et al. 2015, Penrose et al. 2016). However, these 
studies were not considered formally, as they did not stratify 
outcomes following MoMHA revision according to the reason 
for revision of the primary MoMHA implant.
Included studies had certain limitations such as small sample 
size, and data quality problems including missing data, which 
can all make synthesis of the available evidence problematic. 
10 of the 15 unique studies involved small cohorts of less 
than 50 ARMD revisions. Apart from the extended follow-up 
report (Matharu et al. 2017b) all studies had a mean follow-up 
after ARMD revision of 5 years or shorter, with most having 
a mean follow-up of 3 years or less. A number of studies did 
not specifi cally provide patient demographics and outcomes 
for the ARMD revision procedures. Some studies reported on 
complications and re-revision surgery but not on post-revision 
functional outcomes, or vice versa (Norris et al. 2014, Stryker 
et al. 2015). 
The patient demographics and outcomes following ARMD 
revision surgery for all included studies are summarized in 
Table 1. Most revisions were performed in females, in young 
patients (under 60 years), and within 5 years of primary 
MoMHA. Revisions were almost equally split between HRAs 
and MoM THAs. The initial systematic review (Matharu et al. 
2014a) concluded that there was limited evidence on outcomes 
following MoM THA revisions performed for ARMD (Munro 
et al. 2014). Therefore a number of studies have subsequently 
reported on the outcomes following MoM THA revisions.
Defi ning ARMD
The term ARMD was introduced in 2010 as an umbrella term 
for painful MoMHA failures with one or more of the following 
features in the absence of another plausible diagnosis (Lang-
ton et al. 2010, Langton et al. 2011): large sterile effusions 
(including pseudotumor), macroscopic tissue necrosis, metal-
losis and ALVAL (or aseptic lymphocytic vasculitis associ-
ated lesions, which refers to a specifi c lymphocyte-dominated 
histopathological appearance). The term ARMD has generally 
been accepted as the most inclusive for describing this het-
erogeneous condition, which can have varying degrees of dis-
ease severity (discussed above in “Intra-operative fi ndings and 
surgical strategy”). Continued research in this particular fi eld 
has resulted in the defi nition for ARMD evolving with time. 
We would make a diagnosis of ARMD in MoMHAs if there 
was cross-sectional imaging and intra-operative evidence of 
a pseudotumor (a cystic, solid, or mixed mass communicat-
ing with the hip joint), or if there was no pseudotumor but 
abnormalities including pathological effusions, signifi cant 
metallosis, synovitis, tissue damage and/or necrosis (Pandit 
et al. 2008, Langton et al. 2010, Langton et al. 2011, Hart et 
al. 2012, Nishii et al. 2012, Lainiala et al. 2015). Ideally this 
would be supported by appropriate histopathological fi ndings, 
namely evidence of lymphocytic infi ltrates (including ALVAL) 
and a phagocytic macrophage response to metal wear debris, 
with or without tissue necrosis (Willert et al. 2005, Campbell 
et al. 2010, Grammatopoulos et al. 2013). However, we rec-
ognize that surgery is planned based on preoperative investi-
gations with any histopathological diagnosis of ARMD typi-
cally available only after revision has been performed. ARMD 
can also coexist with other abnormalities (such as loosening, 
osteolysis, instability) in the same way, for example, infec-
tion can coexist with other abnormalities (De Smet et al. 2011, 
Matharu et al. 2014b).
Of the 15 unique studies reviewed, which reported out-
comes following ARMD revision, all provided some defi ni-
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tion for ARMD. However, only 11 studies provided enough 
details about both the clinical and histopathological features 
to satisfy our working diagnosis of ARMD (Grammatopoulos 
et al. 2009, De Smet et al. 2011, Rajpura et al. 2011, Liddle et 
al. 2013, Matharu et al. 2014b, Munro et al. 2014, Norris et al. 
2014, Pritchett 2014, Cip et al. 2015, Lainiala et al. 2015, Liow 
et al. 2016). No study formally stated how it dealt with mul-
tiple revision indications (e.g., by using a hierarchy to estab-
lish the primary diagnosis for revision). However, it was clear 
from the data presented that most studies had reported cases of 
ARMD alone, as well as ARMD coexisting with other abnor-
malities (such as loosening, osteolysis, instability). In addition 
to this variability between studies when diagnosing ARMD it 
is important to note that the diagnosis can be subjective even 
when the same criteria are used, with various surgeons poten-
tially interpreting any abnormal features differently. Although 
reviews of the literature like the present one are inherently 
limited by the quality and reporting of the published studies 
reviewed, the variability in how ARMD has been diagnosed in 
the different studies has important implications when making 
comparisons between studies and must be considered when 
interpreting our review of the literature.
Complications and re-revision surgery
The frequency of complications (up to 68%) and re-revision 
surgery (up to 38%) were variable amongst the short-term 
studies but generally high (Table 1). In the fi rst 16 ARMD 
revisions performed at 1 center there was an increase in the 
frequency of complications (50% to 69%) and re-revision 
(38% to 44%) from the initial study at a mean of 3 years fol-
low-up (Grammatopoulos et al. 2009) to the report at a median 
of 10 years (Matharu et al. 2017b). Some studies did report 
implant survival rates following ARMD revision, which were 
88% at both 3 years (Liow et al. 2016) and 5 years (Matharu 
et al. 2014b), and 56% at 10 years (Matharu et al. 2017b). 
Recent data from the NJR for England and Wales reported 
that following 2,535 ARMD revision procedures in MoMHA 
patients the 5-year implant survival rate was 90% (Matharu 
et al. 2017a). This was similar to the 5-year implant survival 
reported in the NJR following all-cause non-MoMHA revi-
sion surgery (88%–89% depending on bearing surface and 
component fi xation) (NJR 2016). Another recent study com-
paring outcomes following all-cause acetabular only revisions 
in MoMHAs with all-cause acetabular only revisions in metal-
on-polyethylene THAs observed similar incidences of local 
complications, dislocation, infection, and re-revision between 
the groups at up to 2-year follow-up (Penrose et al. 2016).
Early observations suggested short-term outcomes follow-
ing ARMD revision were poor, with half of patients sustain-
ing major complications and over one-third requiring further 
operations (Grammatopoulos et al. 2009). Similar observa-
tions were reported in subsequent small cohorts reporting their 
initial experience following ARMD revision surgery (Rajpura 
et al. 2011, Munro et al. 2014). Furthermore the frequency of 
complications and re-revision following the fi rst ARMD revi-
sion cases were higher compared with MoMHA revisions for 
non-ARMD indications (fracture, loosening, infection), and 
compared with matched patients undergoing primary conven-
tional THA (Grammatopoulos et al. 2009). The poor outcomes 
following ARMD revision were thought to relate to the inva-
sive and destructive nature of these lesions (Pandit et al. 2008, 
Grammatopoulos et al. 2009, Langton et al. 2010, Haddad 
et al. 2011). In addition to regular MoMHA patient surveil-
lance these initial observations led regulatory authorities and 
orthopedic surgeons to widely recommend performing early 
revision in MoMHAs with ARMD (Grammatopoulos et al. 
2009, De Smet et al. 2011, Haddad et al. 2011, MHRA 2012, 
FDA 2013). It was thought that this strategy would improve 
outcomes following ARMD revision. Therefore over time sur-
geons subsequently adopted a lower threshold for performing 
revision for ARMD.
There is evidence to suggest that outcomes following 
ARMD revision in MoMHAs may have improved with time. 
The reason for this is likely multifactorial and may include 
regular patient surveillance, lowering of the threshold for per-
forming revision, increasing surgical experience with ARMD 
revisions (including employing different strategies to manage 
soft-tissue and bone damage, and reduce ARMD recurrence), 
and patients now undergoing revision at longer intervals from 
primary surgery rather than early after MoMHA.
One single surgeon series observed that the frequency of 
complications and re-revisions were signifi cantly reduced in 
their latest 31 ARMD revision cases compared with their fi rst 
17 revisions (De Smet et al. 2011). In addition to lowering the 
threshold for performing ARMD revisions in the later cases 
the surgeon made numerous other changes to their practice 
including more intensive surveillance with routine blood 
metal ion sampling, revising both HRA components, implant-
ing larger ceramic femoral head sizes, and postoperatively 
using anti-dislocation braces. Furthermore outcomes follow-
ing ARMD revision were not signifi cantly inferior compared 
with the 65 non-ARMD HRA revisions performed by the 
same surgeon (De Smet et al. 2011). Although this was con-
trary to earlier observations (Grammatopoulos et al. 2009), we 
acknowledge that when this initial cohort were reviewed at 
extended follow-up there was no longer a difference in the 
frequency of complications and re-revision following ARMD 
revisions compared with non-ARMD revisions (Matharu et al. 
2017b). 
2 of the largest and more recent studies (Table 1) have 
reported the lowest frequency of complications and re-revi-
sion (Pritchett 2014, Lainiala et al. 2015). 1 study was a 
single surgeon series of 90 revisions (Pritchett 2014), and the 
other was the largest published study involving 215 ARMD 
revisions performed by six surgeons (Lainiala et al. 2015). 
Therefore ARMD revisions performed in specialist centers 
by experienced and high-volume MoMHA revision sur-
geons, not surprisingly, seem to also lead to better outcomes, 
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Table 1. Studies reporting the outcomes following metal-on-metal hip arthroplasty revision surgery performed for ARMD
A  B C D E F G H I J 
Grammatopoulos et al.    16 R 100%   51.3  1.6 a  3.0 a 50%  38%  Dislocation ± ARMD Mean OHS 
 (2009)  (16) (20–71) (0.01–6.7) (0.8–7.2) (8) (6) recurrence (4) 20.9  
         Loose cup (2)
Rajpura et al. (2011)   11 R 36%  53.5  3.8  1.8 18% 18% ARMD recurrence (2) Mean OHS
   (4) (22–67) (1.3–7.3) (1.0–3.3) (2) (2)  35.3
De Smet et al. (2011)   48 R 61%  52.5  2.7  3.3 a < 23% < 13% Loose cup or stem (2) Mean HHS
   (NS) a (18–71) (0.3–8.4) (0.3–10.1)  (11) a (6) * Infection (2) 93.1 a
         ARMD recurrence (1) 
Ebreo et al. (2011)   42 55% Median  4.7 a  2.2 a ≤ 10%  ≤ 2%   Infection (1) Mean OHS
    R+T (23)  61 (NS) (1.3–7.8) (1.2–4.0)  (4) a (1) a  23.7 a
Liddle et al. (2013)   32 R 81%  57.7  4.3 Median 2.5 ≤ 6% ≤ 6% Dislocation (1) Median OHS
   (26) (25–74) (0.9–10.9) (1.0–4.5) a   ARMD recurrence with 36.5 a 
         loose cup (1)   
Su and Su (2013)   13 R 85% NS NS  2.3 a ≤ 15% ≤ 15%  Infection (2) Mean HHS
    (11)   (0.7–6.7)  (2) a (2) a  96.4
Munro et al. (2014)   19 T 37%    57.5  2.8 a  2.1 a 68% 21% Dislocation and/or Mean WOMAC
   (NS) a (46–76) (0.6–4.9) (0.8–4.0) (13) (4) loose cup (3) (pain) 78
         ARMD recurrence (1) (function) 83  
Pritchett (2014)   90 R 48%  49.8  2.8  5.1 4% 3% ARMD recurrence (1) Mean HHS
   (43) (32–71) (1.3–4.9) (3.0–9.8) (4) (3) Infection (1) 93.2
         Loose cup (1) 
Matharu et al. (2014b)   46 R 72%  57.8  5.5  4.5 20%  13% Dislocation (2) Median OHS
    18 T (46) (31–79) (1.1–13.8) (1.0–14.6) (13) (8) ARMD recurrence (2) 39
Norris et al. (2014)   35 R 71%  58.0  4.3 NS NS NS NS Mean OHS 33
   (25) (30–76) (1.5–9.6)  
Cip et al. (2015)   20 T 47%  49.6 a  4.6 a  2.3 10% 5% Infection (1) Mean HHS
   (NS) a (21–61) (2.7–6.7) (1.5–3.1) (2) (1)  85.1
Stryker et al. (2015)   58 T 65%  60.0 a  3.9 a  1.2 a 20% 16% Infection (7) NS
   (NS) a (17–84) (0.1–9.5) (0–10.2)  (23) (18) Loose cup or stem (6)
         Dislocation (4) 
Lainiala et al. (2015)   49 R 60%  62.1  4.7   2.3 5% 3% Dislocation (4) Median OHS
  166 T (130) (SD 10.1) (SD 1.3) (1.0–NS) (11) (6) Infection (1) 40
van Lingen et al. (2015)   38 T 69%  63.0 a Median 3.7  3.1 a 24% 8% Dislocation (3) Mean HOOS 
   (NS) a (44–75) (1.0–6.5) a (2.1–4.7) (9) (3)  61.9 a
Liow et al. (2016)   25 R 36%   62.0  5.1  2.5 14% 7% ARMD recurrence (3) Mean HSS
    77 T (35)  (41–85) (1.4–18.3) (2.2–4.3) (14) (7) Dislocation (2) 75.6
         Loose cup (2) 
Matharu et al. (2017b) b    16 R 100%  51.3  1.6 a Median 10.3 69% 44% Dislocation ± ARMD Median OHS
   (16) (20–71) (0.01–6.7)  (7–15) a (11) (7) recurrence (5) 21
         Loose cup (2)  
NS = not stated, SD = standard deviation
A. Study author and year 
B. Hips revised for ARMD (adverse reactions to metal debris)
 R: Resurfacing arthroplasty
 T: Total hip arthroplasty 
C. Female hips, % (n) 
D. Mean age (range) at revision in years 
E. Mean time to revision (range) in years 
F. Mean follow-up time after revision (range) in years 
G. Frequency of complications, % (n) 
H. Frequency of re-revision, % (n) 
I. Main reasons for re-revision surgery, % (n) 
j. Functional outcome: Functional outcome scoring systems: OHS (Oxford Hip Score) = 0–48 (48 best outcome) (Dawson et al. 1996, Murray 
 et al. 2007); HHS (Harris Hip Score) = 0–100 (100 best outcome) (Harris 1969); HOOS (Hip disability and osteoarthritis outcome score) = 
 0–100 (100 best outcome) (Klassbo et al. 2003); WOMAC (Western Ontario and McMaster Universities Arthritis Index) = 0–100 (0 best out- 
 come) (Bellamy et al. 1988).
a Studies did not provide the relevant data specifi cally for the cohort of patients undergoing revision for adverse reactions to metal debris (but 
  rather for the whole cohort of metal-on-metal hip arthroplasty revisions that they reported on).
b Updated report on Grammatopoulos et al. (2009)
which has been postulated previously (De Smet et al. 2011, 
Liddle et al. 2013). Recent registry data suggest a weak effect 
between the time interval between primary and revision for 
ARMD and re-revision rates, with revisions performed early 
after MoMHA more likely to require re-revision (Matharu 
et al. 2017a). This is plausible given MoMHAs are scarcely 
implanted now, thus the time interval between primary and 
revision for patients with MoMHAs now developing ARMD 
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is increasing. It is therefore suspected that those presenting 
with ARMD nowadays will tend to have more benign disease 
and hence better outcomes following revision compared with 
the aggressive and destructive lesions observed in MoMHAs 
which required early revision for ARMD (Grammatopoulos et 
al. 2009, Munro et al. 2014).
A recent NJR analysis of MoMHA revisions compared 
the subsequent outcomes in 1,288 ARMD revisions matched 
to 1,288 non-ARMD revision indications (Matharu et al. 
2018b). That study observed that patients revised for ARMD 
had approximately half the risk of re-revision compared with 
patients undergoing non-ARMD revision surgery. This was 
contrary to the initial observations (Grammatopoulos et al. 
2009, Rajpura et al. 2011, Munro et al. 2014). The authors 
concluded that surgeons and worldwide regulatory authorities 
have positively infl uenced outcomes following ARMD revi-
sion by promoting regular patient surveillance and widely rec-
ommending a lower threshold for performing revision surgery 
(Matharu et al. 2018b). Interestingly the highest risk of re-
revision surgery was when MoMHAs were revised for infec-
tion and dislocation/subluxation (5-year implant survival rates 
of 81% and 82% respectively) (Matharu et al. 2018b).
Reasons for re-revision surgery
In line with previous evidence (Matharu et al. 2014a), the 
commonest indications for re-revision surgery following 
ARMD revision in the included studies were dislocation, 
ARMD recurrence, aseptic component loosening, and infec-
tion (Table 1).
Dislocation can be related to ARMD lesions that are 
destructive and/or require extensive soft-tissue debridement. 
Both can compromise the hip abductors and/or short exter-
nal rotators and therefore lead to hip instability (De Smet et 
al. 2011). Other risk factors for dislocation include reducing 
the large-diameter MoM bearing when exchanging to a non-
MoM articulation, and not correcting any residual component 
malposition at ARMD revision (for example when perform-
ing modular revisions in MoM THAs) (Stryker et al. 2015). 
Using large femoral head sizes (>36 mm) at ARMD revision 
has not prevented dislocations (Munro et al. 2014). This sug-
gests that instability following ARMD revision is a complex 
problem, with some surgeons using anti-dislocation braces, 
dual-mobility acetabular components, and an overall lower 
threshold for performing ARMD revision procedures in an 
attempt to reduce the subsequent dislocation risk (De Smet et 
al. 2011, Pritchett 2014).
Most studies have reported at least 1 case of ARMD recur-
rence following ARMD revision (see Table 1). Recurrence can 
occur due to incomplete excision of metal debris at revision. 
Reasons for incomplete excision include surgical error and 
being unable to excise all the metal debris because of its prox-
imity to vital neurovascular structures (Grammatopoulos et al. 
2009, Liddle et al. 2013). In such cases serial post-revision 
cross-sectional imaging can be useful for monitoring progres-
sion of any residual ARMD (Grammatopoulos et al. 2009, 
Munro et al. 2014). Recurrence of ARMD can also occur if 
there is another potential source of metal wear debris and/
or corrosion, including implantation of another MoM bear-
ing (Liddle et al. 2013, Matharu et al. 2014b, Pritchett 2014) 
or using a cobalt-chrome femoral head on a titanium alloy or 
cobalt-chrome femoral stem (Munro et al. 2014, Whitehouse 
et al. 2015, Plummer et al. 2016). In light of these observa-
tions most surgeons now use ceramic femoral heads when 
performing ARMD revisions (Grammatopoulos et al. 2009, 
De Smet et al. 2011, Liddle et al. 2013), with a taper adapter 
used if the stemmed femoral component is retained given the 
theoretical risk of ceramic head fracture when impacted onto 
retained tapers (Plummer et al. 2016).
Aseptic loosening, usually of the acetabular component, 
may be due to invasive and destructive ARMD causing sig-
nifi cant osteolysis and/or iatrogenic bone loss when remov-
ing a well-fi xed component, which increases the risk of failed 
implant osseointegration. 1 study experienced a number 
of failures due to aseptic acetabular loosening despite the 
absence of bone defects, but this was thought to be due to the 
fi ber metal-backed acetabular components implanted at revi-
sion, with better results obtained when porous tantalum com-
ponents were used (Munro et al. 2014).
Risk factors for infection may include multiple operations, 
incomplete excision of metal debris or necrotic tissue at revi-
sion, and the retention of primary MoMHA components 
(Liddle et al. 2013, Munro et al. 2014).
Functional outcomes
Patient-reported outcomes after the initial ARMD revisions 
were poor (Grammatopoulos et al. 2009, Ebreo et al. 2011, 
Munro et al. 2014), with these also being inferior compared 
with MoMHA revisions for non-ARMD indications, and com-
pared with primary conventional THAs (Grammatopoulos et 
al. 2009). The poor functional outcomes reported in an early 
study of 16 ARMD revisions (Grammatopoulos et al. 2009) 
persisted at extended follow-up, and remained inferior com-
pared with MoMHA revisions for non-ARMD indications 
(Matharu et al. 2017b). These poor functional outcomes were 
also considered a consequence of the invasive and destructive 
nature of ARMD lesions, with a lower threshold for perform-
ing such revision procedures widely adopted (Grammato-
poulos et al. 2009, De Smet et al. 2011, Haddad et al. 2011, 
MHRA 2012, FDA 2013).
The majority of subsequent studies have reported good or 
excellent functional outcomes following ARMD revision (De 
Smet et al. 2011, Rajpura et al. 2011, Liddle et al. 2013, Su 
and Su 2013, Matharu et al. 2014b, Pritchett 2014, Cip et al. 
2015, Lainiala et al. 2015), defi ned as a mean Oxford Hip 
Score (OHS) of 34 or above or a Harris Hip Score (HHS) of 
80 or above (Harris 1969, Kalairajah et al. 2005, Murray et al. 
2007). However, not all of the more recent studies achieved 
good functional outcomes following ARMD revision (Norris 
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et al. 2014, van Lingen et al. 2015, Liow et al. 2016), which 
suggests other factors may infl uence outcomes after these pro-
cedures.
Predicting re-revision and guiding surgical decisions
Identifying prognostic factors of outcome following ARMD 
revision would provide surgeons with thresholds for perform-
ing revision and help guide decisions regarding the type of 
reconstruction to perform. However, most of the evidence 
regarding factors predictive of poor outcomes following 
ARMD revision surgery is limited to small studies that were 
not adequately powered to identify prognostic factors (De 
Smet et al. 2011, Liddle et al. 2013, Matharu et al. 2014b, 
Liow et al. 2016).
In some of the earliest MoMHAs revised for ARMD a sig-
nifi cantly higher risk of re-revision and inferior functional 
outcomes were reported when another MoM bearing was 
implanted at revision (Liddle et al. 2013, Matharu et al. 2014b, 
Pritchett 2014). This is suspected to be due to the continued 
source of metal wear debris and/or corrosion, and has led to 
using non-MoM bearing surfaces at ARMD revision. Solid 
pseudotumors have been a risk factor for re-revision surgery 
following ARMD revision (Liddle et al. 2013). Similarly a 
recent study of 102 ARMD revisions identifi ed MARS-MRI 
evidence of solid lesions with abductor defi ciency to be pre-
dictive of post-revision complications, with pre-revision 
radiographic implant loosening also predicting poor outcomes 
(Liow et al. 2016). However, this study did not fi nd other fac-
tors to be predictive of post-revision complications, such as 
pre-revision blood metal ions, type of revision articulation, 
and femoral head size (Liow et al. 2016).
Recent analysis of NJR data identifi ed 4 predictors of re-
revision surgery following ARMD revision in MoMHAs: 
high BMI at revision, modular component only THA revi-
sions (exchange of the head and liner only with/without taper 
adapter), ceramic-on-ceramic revision bearings, and acetab-
ular bone grafting (Matharu et al. 2017a). The authors con-
cluded that as these predictors included modifi able factors 
(type of THA revision procedure, revision bearing surface, 
and possibly the use of acetabular bone graft) surgeons could 
potentially reduce failure rates further following ARMD revi-
sion. By contrast, smaller studies from the Australian Joint 
Replacement Registry have reported that re-revision following 
aseptic MoM HRA revision surgery was not infl uenced by the 
type of revision procedure performed or the revision bearing 
surface implanted (de Steiger et al. 2010, Wong et al. 2015).
Conclusions
Numerous studies have now reported on the short- to medium-
term risks associated with ARMD revision surgery in MoMHA 
patients, which can be used to counsel patients informatively 
pre-revision. Evidence suggests that outcomes following 
ARMD revision may have improved with time. The reason 
for this is multifactorial and may include regular patient sur-
veillance, lowering of the threshold for performing revision, 
surgical experience with ARMD revisions, and patients now 
undergoing revision at longer intervals from primary surgery 
with such cases potentially being less severe compared with 
revisions performed early after MoMHA. However, we con-
sider that the threshold for performing ARMD revision sur-
gery need not be lowered much further as this introduces the 
potential for surgical risk to outweigh any benefi ts.
By contrast, robust thresholds for performing ARMD revi-
sion surgery are lacking. Although non-registry studies have 
attempted to identify predictors of cross-sectional imaging 
progression (Reito et al. 2014, Briant-Evans et al. 2015, Kwon 
et al. 2016, Matharu et al. 2016a), and predictors of poor out-
comes following ARMD revision (De Smet et al. 2011, Liddle 
et al. 2013, Matharu et al. 2014b, Dimitriou et al. 2016), these 
have been short-term studies that were underpowered for iden-
tifying predictors. Recent registry data suggest that modifi able 
factors exist which may allow surgeons to reduce failure rates 
further following ARMD revision (Matharu et al. 2017a), 
although these require validation.
Future studies should focus on obtaining good quality evi-
dence to develop robust thresholds for performing ARMD 
revision surgery and to inform the surgical strategy at ARMD 
revision, which will both assist surgeons when managing 
MoMHA patients. Most of these questions require large well-
designed multi-center studies with extended follow-up that 
can assess potentially important predictors of complications, 
re-revision, and functional outcomes following ARMD revi-
sion surgery (such as pre-revision blood metal ion levels and 
cross-sectional imaging fi ndings). These issues simply cannot 
be addressed using current arthroplasty registries, which do 
not collect such data. Multi-center studies would provide 
important information on the role of blood metal ions and 
cross-sectional imaging in predicting disease severity, tissue 
destruction, and outcomes following ARMD revision. This 
information can then be used to guide thresholds for perform-
ing ARMD revision. Both multi-center studies and retrospec-
tive registry cohorts are required to inform the surgical strat-
egy at ARMD revision, which will include establishing the 
optimal implant fi xation methods, the optimal bearing surface 
(comparing highly cross-linked polyethylene articulating with 
ceramic vs. metal heads), and the management of instability in 
association with soft-tissue problems (dual mobility cups vs. 
constrained acetabular liners). Finally, the long-term systemic 
effects of metal ion exposure in MoMHA patients must also be 
investigated, particularly the potential oncological and cardiac 
consequences. This will also help establish whether there are 
any systemic reasons to recommend revision of MoMHAs in 
the absence of local ARMD. Addressing the outlined research 
questions would allow a more evidence-based approach for 
the management of MoMHA patients who may require revi-
sion for ARMD.
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